Bioventus Launches Durolane OA Treatment in Taiwan

Bioventus launched its DUROLANE® single-injection hyaluronic acid-based osteoarthritis (OA) treatment in Taiwan, to be marketed by Eulogiums for mild to moderate knee OA.

Bioventus' orthobiologic products are now available in six countries in the Asia Pacific region.


document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us